Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options
- PMID: 17702711
- DOI: 10.2215/CJN.04351206
Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options
Abstract
IgA nephropathy is one of the most common causes of glomerulonephritis in the world. Proliferative and crescentic forms of IgA are found in up to 30% of cases and are associated with nephrotic-range proteinuria, accelerated hypertension, and accelerated decline toward ESRD. Despite its prevalence and clinical importance, there is no unifying nomenclature or consensus for the treatment of specific histologic subgroups. As a consequence, the development of clinically effective treatment regimens for IgA nephropathy have lagged behind other, less common forms of glomerulonephritis. Herein is reviewed the pathogenesis and histologic subtypes of IgA nephropathy and how conventional and immunosuppressive therapies have an impact on renal survival and recurrence rates. The use of known clinical risk factors for disease progression in conjunction with specific histologic features can be a guide to both induction and consolidation therapies for individual patients with IgA nephropathy.
Similar articles
-
Recurrent or de novo IgA nephropathy with crescent formation after renal transplantation.Ren Fail. 2008;30(6):611-6. doi: 10.1080/08860220802134516. Ren Fail. 2008. PMID: 18661411
-
The pathogenesis and treatment of IgA nephropathy.Fukushima J Med Sci. 2008 Dec;54(2):43-60. doi: 10.5387/fms.54.43. Fukushima J Med Sci. 2008. PMID: 19418967 Review.
-
IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes.Nephrol Dial Transplant. 2008 Aug;23(8):2537-45. doi: 10.1093/ndt/gfn014. Epub 2008 Feb 10. Nephrol Dial Transplant. 2008. PMID: 18263928
-
Histology and immunohistology of IgA nephropathy.J Nephrol. 2005 Nov-Dec;18(6):676-80. J Nephrol. 2005. PMID: 16358224 Review.
-
Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy.Semin Nephrol. 2004 May;24(3):256-68. doi: 10.1016/j.semnephrol.2004.01.006. Semin Nephrol. 2004. PMID: 15156530
Cited by
-
Co-Delivery of Dexamethasone and Captopril by α8 Integrin Antibodies Modified Liposome-PLGA Nanoparticle Hybrids for Targeted Anti-Inflammatory/Anti-Fibrosis Therapy of Glomerulonephritis.Int J Nanomedicine. 2022 Mar 30;17:1531-1547. doi: 10.2147/IJN.S347164. eCollection 2022. Int J Nanomedicine. 2022. PMID: 35388271 Free PMC article.
-
Mesangial pathology in glomerular disease: targets for therapeutic intervention.Adv Drug Deliv Rev. 2010 Nov 30;62(14):1337-43. doi: 10.1016/j.addr.2010.08.011. Epub 2010 Sep 7. Adv Drug Deliv Rev. 2010. PMID: 20828589 Free PMC article. Review.
-
Sublytic C5b-9 triggers glomerular mesangial cell apoptosis via XAF1 gene activation mediated by p300-dependent IRF-1 acetylation.Cell Death Dis. 2014 Apr 17;5(4):e1176. doi: 10.1038/cddis.2014.153. Cell Death Dis. 2014. PMID: 24743731 Free PMC article.
-
Neuroblastoma suppressor of tumorigenicity 1 is associated with the severity of interstitial fibrosis and kidney function decline in IgA nephropathy.J Nephrol. 2023 Nov;36(8):2245-2256. doi: 10.1007/s40620-023-01704-x. Epub 2023 Jul 12. J Nephrol. 2023. PMID: 37436574
-
Chronic kidney disease prevention--a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives.Clin Exp Nephrol. 2012 Apr;16(2):187-94. doi: 10.1007/s10157-012-0592-8. Epub 2012 Mar 3. Clin Exp Nephrol. 2012. PMID: 22389158
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous